What is common between Celltrion, Samsung Bioepsis, Biocon and
Oncobiologics ??????
All these companies are actively promoting themselves as one of
the leading contract manufacturing companies for both
Biopharmaceuticals and Biopahrma production and have formed alliances with
major companies in the regulated market during Biosimilar drug development
process. The first three already have marketed products in regulated market and
Oncobiologics which was formed in year 2011 has already finished P1 clinical
studies for ONS -3010 (Humira Biosimilar) and ONS- 1045 (Avastin Biosimilar and
i assume the said mAb's to enter P3 clinical studies by early 2016
In the span of less than 10 years these companies have evolved as
a major biosimilar developer in their specific countries...its a
great achievement till now....
Now we need to see how the generic players who have already
marketed products and are developing their Biosimilar portfolio will
be evolving as a third party vendor in the developing world for the
major Pharma's. Let see how the landscape evolve in the coming years.....
No comments:
Post a Comment